Company profile: Phylos
1.1 - Company Overview
Company description
- Provider of molecular genetics–driven breeding solutions for hemp and cannabis, delivering pure, uniform, and vigorous seeds and clones, including fully feminized Elite F1 hybrid and production-ready seeds; Natural THCV genetics licensed through partnerships; variety licensing; genotype testing; and field-based grower support with trials and best practices.
Products and services
- Production-Ready Seed: Production-ready seeds enabling cultivators to grow uniform, high-performing cannabis plants directly from seed without cloning, delivering consistent performance and vigor for grower success
- Elite F1 Hybrid Seeds: Fully-feminized F1 hybrid cannabis seeds engineered for uniformity, high THC, unique aromas, and stress tolerance for cannabis cultivation, ensuring reliable crop performance
- Genotype Test: Genomic testing product validating cannabis and hemp strains for growers and breeders, confirming strain identity and consistency to support breeding and cultivation choices
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Phylos
GreenLight Biosciences
HQ: United States
Website
- Description: Provider of RNA-based solutions for agriculture and human health, offering a proprietary platform to produce RNA at scale cost-effectively and products targeting pests and diseases without harming beneficial insects, including Varroa mite control for honeybees and Calantha, an EPA-approved RNA product for Colorado Potato Beetle control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GreenLight Biosciences company profile →
Verge Genomics
HQ: United States
Website
- Description: Provider of an AI-powered, all-in-human drug discovery platform (CONVERGE®) integrating proprietary human genomics and computational tools to predict new drugs; developer of VRG50635, a PIKfyve inhibitor for ALS; and collaborator with industry and academic partners, including Alexion/AstraZeneca Rare Disease, Eli Lilly, and SITraN, to co-develop clinical-stage and novel therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Verge Genomics company profile →
WestBred
HQ: United States
Website
- Description: Provider of highest yield potential wheat seed designed for regional conditions, including certified single-variety seed containing no other crops, foreign material, or certain seed-borne diseases; Clearfield Plus production system for grass and broadleaf weed control using Beyond herbicide; grower resources such as optimal seeding rate guidance; intellectual property protection for varieties; and the National Wheat Yield Contest.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full WestBred company profile →
Immunostep
HQ: Spain
Website
- Description: Provider of flow chemistry products and services for diagnostic and research applications, including antibodies and conjugates, recombinant proteins, vials, staining solutions, and stability reagents, plus mono- and polyclonal development and peptide production. Offers kits for flow cytometry such as HeMoStep, apoptosis and basophil activation, platelet immunoglobulin and COVID-19 tests, and the ExoStep exosome platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunostep company profile →
Omniome
HQ: United States
Website
- Description: Provider of a proprietary DNA sequencing platform delivering high-accuracy short-read sequencing using Sequencing by Binding (SBB) chemistry. Offers the Onso hardware and software system; validated exome/panel sequencing; single-cell RNA-Seq solutions; and tools for cancer research and gene editing, with lower error rates than traditional sequencing by synthesis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Omniome company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Phylos
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Phylos
2.2 - Growth funds investing in similar companies to Phylos
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Phylos
4.2 - Public trading comparable groups for Phylos
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →